Mangoceuticals, Inc. Common Stock (MGRX) — Working Capital to Net Assets Ratio
Mangoceuticals, Inc. Common Stock (MGRX) has a Working Capital to Net Assets ratio of -1.3% as of September 2025. Working capital of $-206.05K (current assets of $598.22K minus current liabilities of $804.27K) is measured against net assets of $15.73 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See MGRX net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Mangoceuticals, Inc. Common Stock Working Capital to Net Assets (2021–2024)
This chart shows how Mangoceuticals, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at -1.3%, reflecting working capital of $-206.05K against net assets of $15.73 Million USD. Check MGRX tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Mangoceuticals, Inc. Common Stock from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see MGRX market cap overview.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -9.7% | $-1.35 Million | $13.95 Million | $75.59K | $1.43 Million | ▼ -88.1 pp |
| 2023 | 78.4% | $607.38K | $774.75K | $818.46K | $211.08K | ▲ +7.7 pp |
| 2022 | 70.7% | $434.03K | $614.03K | $694.61K | $260.58K | ▼ -29.3 pp |
| 2021 | 100.0% | $-16.72K | $-16.72K | $22.55K | $39.27K | — |